摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R,4R,9S,10R,Z)-4,9-dihydroxy-3-methyl-10-pentyl-3,4,7,8,9,10-hexahydro-2H-oxecin-2-one

中文名称
——
中文别名
——
英文名称
(3R,4R,9S,10R,Z)-4,9-dihydroxy-3-methyl-10-pentyl-3,4,7,8,9,10-hexahydro-2H-oxecin-2-one
英文别名
(Z,3R,4R,9S,10R)-3,4,7,8,9,10-hexahydro-4,9-dihydroxy-3-methyl-10-pentyloxecin-2-one;(Z)-cytospolide D;Z-cytospolide-D;Cytospolide D
(3R,4R,9S,10R,Z)-4,9-dihydroxy-3-methyl-10-pentyl-3,4,7,8,9,10-hexahydro-2H-oxecin-2-one化学式
CAS
——
化学式
C15H26O4
mdl
——
分子量
270.369
InChiKey
KLJUONGZMIGRSR-JOROPEEXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.19
  • 重原子数:
    19.0
  • 可旋转键数:
    4.0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    66.76
  • 氢给体数:
    2.0
  • 氢受体数:
    4.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • First total synthesis of the E- and Z-isomers of cytospolide-D
    作者:Ahmed Kamal、Moku Balakrishna、Papagari Venkat Reddy、Abdul Rahim
    DOI:10.1016/j.tetasy.2013.12.004
    日期:2014.1
    A simple, convergent, and efficient approach for the total synthesis of the bioactive E- and Z-isomers of cytospolide-D is described. The key features of the synthetic strategy include stereoselective methylation, regioselective epoxide opening, olefin cross-metathesis, and a Yamaguchi protocol reaction for the formation of the E-olefinic geometry of the 10 membered ring; Steglich esterification and
    描述了用于胞嘧啶-D的生物活性E-和Z-异构体的全合成的简单,收敛和有效的方法。合成策略的关键特征包括立体选择性甲基化,区域选择性环氧化物开环,烯烃交叉复分解和形成10元环E-烯烃几何结构的Yamaguchi协议反应。Steglich酯化反应和闭环易位反应可形成骨架中具有Z烯烃几何结构的10元环。1-苹果酸用作构建烯酸片段的手性库起始原料,而d-甘露醇用作构建烯醇片段的手性库起始原料。
  • Chemoenzymatic Asymmetric Total Synthesis of Nonanolide (<i>Z</i>)-Cytospolides D, E and Their Stereoisomers
    作者:Rohan Kalyan Rej、Samik Nanda
    DOI:10.1002/ejoc.201301365
    日期:2014.2
    asymmetric total synthesis of the (Z)-isomer of the naturally occurring decanolide cytospolides D, E and six stereoisomers is reported. The main highlight of the synthetic venture involves ring-closing metathesis (RCM) reaction of a suitably functionalized ester compound, which was assembled by the Yamaguchi coupling of the required acid and alcohol fragments. The alcohol fragment was accessed by two
    据报道,天然存在的癸内酯细胞质 D、E 和六种立体异构体的 (Z)-异构体的化学酶不对称全合成。该合成企业的主要亮点涉及适当官能化的酯化合物的闭环复分解 (RCM) 反应,该反应通过所需的酸和醇片段的 Yamaguchi 偶联组装而成。醇片段通过两种替代的化学酶促过程获得,一种是羟腈裂解酶介导的氢氰化,而脂肪酶催化的酯交换是第二种途径中的关键 sep。酸片段是通过前手性 2-甲基-1,3-丙二醇和 Corey-Bakshi-Shibata (CBS) 介导的立体选择性羰基还原的对映选择性酶解对称 (EED) 构建的。
查看更多

同类化合物

胰岛素原(cattle),29-[N6-[[2-(甲磺酰)乙氧基]羰基]-L-赖氨酸]-59-[N6-[[2-(甲磺酰)乙氧基]羰基]-L-赖氨酸]-(9CI) 十氢-2,7-苯并二氧杂环癸烷-3,6-二酮 二环<3.3.0>-2-氧杂-5-(2-丙烯基)-1-辛烯 乙烯邻苯二甲酸酯 [(E,1R)-1-[(2R,4Z,7S,8R)-7-溴-8-乙基-3,6,7,8-四氢-2H-氧杂环辛三烯-2-基]己-3-烯-5-炔基]乙酸酯 [(2R,3S,4E,6R,7S)-6,7-二羟基-2-甲基-10-氧代-2,3,6,7,8,9-六氢氧杂环辛三烯-3-基] (E)-丁-2-烯酸酯 6,7-二氢-5aH-氧杂环丁烷并[3,2-d][1,3]苯并二氧戊环 5-氧杂-10-氮杂三环[5.3.1.03,8]十一碳-1(10),2,6,8-四烯 3-氧杂二环[3.3.1]壬-6-烯-9-酮 3,4,5,6-四氢-2,7-苯并二氧杂环癸烷e-1,8-二酮 10-(乙酰氧基)-4,5,6,7-四氢-2H-1-苯并氧杂环辛三烯-2,8(3H)-二酮 1-(2,3,4,5-四氢-1,6-苯并二噁辛英-8-基)丙烷-1-酮 1,2-环己烷二甲酸1-甲基-1,2-乙二基酯 (S)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯 (7Z)-2-(3-溴丙-1,2-二烯基)-5-(1-溴丙基)-3,3a,5,6,9,9a-六氢-2H-呋喃并[3,2-b]氧杂环辛三烯 (7E)-4,7-二羟基-10-甲基-3,4,5,6,9,10-六氢氧杂环辛三烯-2-酮 (6Z)-10-甲基-3,4,5,8,9,10-六氢-2H-氧杂环辛三烯-2-酮 (5Z,8S)-3-氯-2-[(E)-戊-2-烯-4-炔基]-8-[(E)-丙-1-烯基]-3,4,7,8-四氢-2H-氧杂环辛三烯 (4Z)-3,6-二氢-2,7-苯并二氧杂环癸烷e-1,8-二酮 (4S,5Z,7S,8S,10R)-4,7,8-三羟基-10-甲基-3,4,7,8,9,10-六氢氧杂环辛三烯-2-酮 (4R,5R,6Z,8S,10R)-4,5,8-三羟基-10-甲基-3,4,5,8,9,10-六氢氧杂环辛三烯-2-酮 (2R,5Z)-8a-[(R)-1-溴丙基]-3a-氯-3,4,7,8-四氢-2a-[(Z)-2-戊烯-4-炔基]-2H-氧杂环辛三烯 1,3,3a,6a-tetrahydro-5-pentyl-4H-cyclopentafuran-4-one trans-1-oxacyclodec-7-ene-2-one 2-epi-herbarumin II (RS)-5-methoxy-2,3,5,6-tetrahydro-8H-benzo[1,4,7]trioxecin β-heptenolactone stagonolide-E fumaric acid butanediyl ester aspinolide A (3R,4R,9S,10R,Z)-4,9-dihydroxy-3-methyl-10-pentyl-3,4,7,8,9,10-hexahydro-2H-oxecin-2-one prelaureatin 8-acetyl-4,4-dimethyl-2,6-dioxo-9-(2-methylpropyl)-2,3,4,5,6,8-hexahydrooxocino[2,3-c]pyrrole 5,6-benzo-2,3-diethoxy-4-oxo-2-hepten-7-olide 3,4,5,6-tetrahydro-oxocin-2-one (Z)-3-butyl-5,6,7,8-tetrahydro-2H-oxocin-2-one presaccharothriolide X 1-{2-[4,5-dihydro-1H-2-benzoxocin-(6Z)-ylidenemethyl]-allyl}-piperidine (R,Z)-8-(methoxymethoxy)-2,2,6,9-tetramethyl-5,6-dihydro-2H-benzo[b]oxocine 5-hydroxy-7R,11-heliannan-10-one 8-methoxy-2,2,6,9-tetramethyl-2H-1-benzoxocin-3(4H)-one 8-methoxy-2,2,6,9-tetramethyl-3,4,5,6-tetrahydro-2H-1-benzoxocin-3-ol (4S,5Z,10R)-4-hydroxy-10-methyl-3,4,7,8,9,10-hexahydro-2H-oxecin-2-one (4R)-9,11-bis(benzyloxy)-4-methyl-4,5,6,7-tetrahydro-1H-benzo[d]-oxecine-2,8-dione ethyl (4Z)-4-methyl-7,8-dihydro-1,3,6-trioxocine-5-carboxylate 4-hydroxy-10-(2-hydroxyethyl)-1,2-dihydro-4,12a-methanooxocino[4,5-b][1,4]benzodioxin-5-one 4-hydroxy-9-(2-hydroxyethyl)-1,2-dihydro-4,12a-methanooxocino[4,5-b][1,4]benzodioxin-5-one (7R,9R,5E)-7-hydroxy-9-propylnon-5-en-9-olide (6S,7R,9R)-6,7-dihydroxy-9-propylnon-4-eno-9-lactone 7-[2-(3,5-Dichloro-N-oxo-pyridin-4-yl)-1-oxoethyl]-10-methoxy-2,3,4,5-tetrahydro-1,6-benzodioxocine